Introduction
FMS-like tyrosine kinase-3 (FLT3) is a receptor tyrosine kinase that is commonly mutated in acute myeloid leukemia (AML). Approximately 23% of patients are found to harbor a constitutively activating FLT3/ITD mutation that confers poor prognosis (1) .
Kinase activating FLT3/PMs such as those reported in the tyrosine kinase domain are also frequently observed (7-10% of patients) (2) . Thus, mutant FLT3 is an attractive therapeutic target in the treatment of this disease.
A number of clinical trials for AML patients with FLT3 mutations have been performed using novel tyrosine kinase inhibitors (TKIs) that target FLT3 (3). However, there have been limitations in the responses observed in patients on these trials, often related to insufficient achievement of thorough FLT3 inhibition. An illustrative example is lestaurtinib (CEP-701), an indolocarbazole that showed activity in Phase 1 and 2 trials, though only in those patients in which a high level of inhibition of FLT3 signaling was 4 achieved. It failed in a randomized Phase 3 trial to improve remission and survival rates for relapsed FLT3 mutant patients for those randomized to chemotherapy plus CEP-701 vs. those receiving chemotherapy alone in part due to failure to achieve inhibition in a large enough fraction of patients (4, 5) . A potential reason for the failure of CEP-701 to effectively inhibit FLT3 signaling in vivo was a high level of human plasma protein binding (6) . This shifts the IC 50 against FLT3 from 2-3nM in assays conducted in media with 10% fetal bovine serum (FBS, typical for most in vitro culture conditions) to 700nM in 100% human plasma (reflective of in vivo binding in patients) (7) .
A number of FLT3 TKI active against FLT3/ITD have little activity against FLT3/PMs, such as the most frequently occurring D835Y mutation. Sorafenib is a biaryl urea compound that targets multiple tyrosine kinases including FLT3/ITD (8) . The results of clinical studies using sorafenib in combination with chemotherapy are promising, demonstrating reduction in bone marrow (BM) and/or peripheral blood (PB) blasts as well as increased CR rates in FLT3/ITD + AML patients (9) (10) (11) . Quizartinib (AC220) is another biaryl urea FLT3 inhibitor that has demonstrated significant responses in FLT3/ITD + AML patients in recent trials (12, 13) . However, both sorafenib and AC220 are inactive against many FLT3/PMs, including the D835Y mutation, and thus do not benefit patients harboring this mutation (14) (15) (16) .
Finally treatment failure has also been observed due to the selection for resistanceconferring point mutations that have appeared in FLT3/ITD-expressing AML patients following TKI treatment. These mutations either occur in residues within the ATP 5 binding pocket or to residues thought to affect protein structure in ways that also affect the binding of the drug allosterically (3) . Midostaurin (PKC412) is a FLT3 TKI that demonstrated reduction of blasts in a Phase 2 trial of relapsed or refractory AML patients (17) and is moderately active against a number of known FLT3/PMs (14) .
However, in a trial of relapsed/refractory AML patients, PKC412 selected for a mutation at residue N676K in a FLT3/ITD patient that conferred drug resistance (18) . A number of initially responsive patients on AC220 and sorafenib trials were also found to have selected for additional resistance-conferring point mutations in the FLT3/ITD allele.
These frequently include a F691L mutation (analogous to the T315I mutation in BCR/ABL that confers resistance to Gleevec) or D835 mutations (Y/F/V/H) in the kinase domain (19, 20) . Crenolanib is a next generation FLT3 inhibitor that is currently in Phase II trials of relapsed AML with FLT3/D835 activating mutations. This compound has demonstrated in vitro and in vivo activity against FLT3/D835 mutations (Y/F/V/H) and the dual FLT3-D835(Y/H)/ITD mutant receptors (21, 22) . However, it is unable to target the F691L mutation, and therefore has the potential to select for this resistance mutation in trials. Currently, the most potent activity against the F691L mutation in vitro has been observed for the BCR-ABL inhibitor ponatinib. However, ponatinib still shows a nearly 20-fold shift in IC 50 for the F691L mutation compared to FLT3/ITD alone, and plasma samples from patients show marginal levels of inhibition in the plasma inhibitory activity (PIA) assay against the F691L mutation and no activity against D835 mutations (23) . Therefore, the search for novel FLT3 TKIs that overcome some of the mechanisms that result in persistent FLT3 activation is necessary to improve the cure rate for this disease.
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We sought to explore the ability of a novel FLT3 inhibitor, TTT-3002, to overcome several mechanisms of drug resistance associated with current FLT3 TKIs. We have previously reported that TTT-3002 is the most potent FLT3 inhibitor discovered to date, with picomolar IC 50 values against FLT3/ITD phosphorylation (24) . Here we assess the activity of TTT-3002 against a broad spectrum of known FLT3/PMs, as well as a number of TKI resistance mutations within the FLT3/ITD allele. Finally, the protein binding characteristics of TTT-3002 in human plasma are explored to predict whether it is likely to maintain activity against FLT3/ITD and FLT3/PM in patients.
Materials and Methods

Compounds
TTT-3002 was a generous gift of Hanno Roder from TauTaTis, Inc. (San Diego, CA).
CEP-701, AC220, sorafenib and PKC412 were purchased from LC Laboratories.
Compounds were dissolved in 100% DMSO and prepared as 10µM stock solutions in RPMI with 0.1% DMSO and stored at -80°C.
Immunoprecipitation and Western Blotting
Cells were cultured in the presence of inhibitor for 1 hour at 37°C, and FLT3 and phospho-FLT3 expression was analyzed by performing immunoprecipitation of whole cell extracts for FLT3 (S-18), followed by SDS-PAGE and Western blotting as described previously (24) . Other proteins were detected from whole cell lysates using the indicated 7 antibodies and a horseradish peroxidase conjugated goat anti-rabbit secondary antibody followed by ECL.
Flow cytometry analysis
Flow cytometry analysis was performed using a BD FACSCalibur machine (BD Biosciences). The following anti-mouse monoclonal antibodies and dyes were used for the staining of cellular markers: CD135-PE, Annexin V-APC, 7-amino-actinomycin (7-AAD, BD Biosciences). For hematopoietic stem/progenitor staining, femur, tibia, hips, and spine were isolated from Ba/F3-F691L/ITD Luc + transplant recipient mice. BM cells were isolated by crushing and stained with anti-mouse CD135-PE (5 µL) for 40 minutes.
Apoptosis was measured by incubating treated cells with Annexin V-APC antibody and 7-AAD for 10 minutes according to the manufacturer's instructions (BD Biosciences). All data were analyzed by FlowJo analysis software (Tree Star).
Macromolecular Modeling
To position TTT-3002, CEP-701, PKC412, AC220 and sorafenib on the FLT3 kinase structure (1RJB) (25) , the kinase domains of the VEGFR2 kinase complexed with sorafenib (4ASD) (26) and the C-terminal Src kinase complexed with staurosporine (1BYG) (27) were superimposed on the FLT3 kinase structure. The program COOT 
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Transplantation of Ba/F3-F691L/ITD luciferase expressing cells was performed as described previously (24, 29) . For engraftment, 2 × 10 
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Statistical analysis was performed with Student's t test by use of the GraphPad software analysis program (Prism) . P values of less than .05 were considered to be statistically significant. All data are presented as the mean ± standard deviation (SD).
Additional information on Materials and Methods can be found online in Supplemental Information.
Results
TTT-3002 activity against FLT3 activating point mutations
Many FLT3 activating point mutations have been observed in AML patients and the response of each FLT3/PM to each FLT3 TKI varies widely (2, 3, (31) (32) (33) (34) . Notably, AC220 has reduced potency against many FLT3/PMs, and is thus ineffective in treating patients with these mutations. To predict the ability of TTT-3002 to inhibit FLT3/PM autophosphorylation, we generated a panel of twelve stably transfected Ba/F3 cell lines in which FLT3/PMs known to transform the cells to IL-3 independence were introduced, and its activity was compared directly to the cytotoxic activity of AC220 (supplemental Table 1 ). This panel included the most frequently occurring D835 mutations (Y/F/V/H) and other D835 variants, as well as I836 mutations and mutations in the juxtamembrane domain (V579A and D593∆). TTT-3002 is a potent inhibitor of all twelve mutants screened, with proliferation IC 50 values in the low nanomolar range, and is thus active against many FLT3/PMs for which AC220 is completely ineffective (Fig. 1A and supplemental Table 1 (Fig. 1B) . TTT-3002 inhibits FLT3/PM phosphorylation in a dose-dependent manner, achieving greater than 50% inhibition of FLT3 signaling at a concentration of 0.5nM (Fig. 1C, D) . In contrast, AC220 failed to achieve thorough FLT3/PM inhibition even at 10nM concentrations (Fig. 1C) . Therefore, TTT-3002's broad spectrum of activity against FLT3/PMs increases its therapeutic potential in patients with this class of non-ITD activating FLT3 mutations.
TTT-3002 activity against FLT3 TKI resistance mutations
The phenomenon of drug resistance caused by selection for FLT3 point mutations is occurring at increasing frequency as higher levels of inhibition by FLT3 TKIs are achieved in clinical trials of FLT3/ITD AML patients (19, 20, (35) (36) (37) . To test the ability of TTT-3002 to successfully treat some of these resistance mutations, site-directed mutagenesis was used to generate a series of FLT3/ITD TKI resistant cell lines (29, 38) . 
Molecular modeling of the TKI-FLT3 binding interaction
To understand the patterns of drug resistance displayed by different FLT3 TKIs in this study, the positions of staurosporine-like (TTT-3002, CEP-701 and PKC412) and sorafenib-like inhibitors (sorafenib and AC220) bound to FLT3 were modeled (Fig. 3) .
Although crystal structures of the FLT3 kinase bound to these inhibitors have not been determined, crystal structures of the related VEGFR2 and C-terminal Src kinases bound to sorafenib (PDB code 4ASD) and staurosporine (PDB code 1BYG), respectively, have been determined (25, 26) . Assuming that these drugs bind similarly to FLT3 kinase, we sorafenib-like inhibitors, respectively, likely leading to steric clashes. Glycine 697 adopts main-chain dihedral angles (phi of 60°, psi of -170°) that are unfavorable for non-glycine amino-acids, and an arginine substitution at this site would also lead to at least local changes in main-chain conformation. It has been proposed that the F691 residue forms a stabilizing π-π stacking interaction with AC220, and thus a mutation to a Leu would result in reduced TKI binding affinity (20) . TTT-3002 is predicted to bind FLT3 without making direct contact with the F691 residue, and thus is unaffected by mutations at this site. Likewise, the closer proximity of F691 and N676 to sorafenib compared to staurosporine atoms likely underlies the trend for substitutions at these sites to confer resistance to sorafenib-like but not staurosporine-like inhibitors.
TTT-3002 overcomes drug resistance in vivo
To assess the ability of TTT-3002 to overcome TKI resistance in vivo, a bioluminescent (Fig. 4E, F) . In contrast, spleen weights and the number of leukemic cells (measured by their expression of CD135) in the BM of TTT-3002 treated mice were significantly reduced (P < 0.01) and these mice appeared healthy at the time of sacrifice (Fig. 4E,   F 
14 resistance. They had relapsed with a dual D835/ITD mutation or D835 point mutation alone while on a FLT3 TKI (Relapse AML 1-3, supplemental Table 2 ). Leukemic blasts from these patients were evaluated for their in vitro sensitivity to TTT-3002, sorafenib and AC220, along with a BM sample from a newly diagnosed FLT3/ITD AML patient sample (AML 1) for comparison. Significant effects on proliferation, induction of apoptosis, and cell signaling were observed when each of these samples was treated with TTT-3002 (Fig. 5A-C, supplemental Table 2 
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Only free, non-protein bound levels of TKI are available to bind to target and inhibit its kinase activity. In order to predict the impact of human plasma protein binding on TTT-3002 efficacy in patients, we utilized the PIA assay, which we developed previously to determine the extent of FLT3 inhibition being achieved in clinical trials of multiple FLT3 TKIs (7). The PIA assay is a valuable tool because human plasma contains the entire array of proteins capable of binding to and thus interfering with a TKI's activity. Utilizing Ba/F3-ITD cells, we compared the IC 50 of TTT-3002 with regard to inhibiting FLT3 phosphorylation (1 h treatment) in media supplemented with 10% FBS (standard culture conditions) to that achieved in 100% mouse or 100% human plasma from healthy donors. We found a 4-and 14-fold shift in IC 50 values, respectively, in mouse and human plasma (Fig. 6A, B and supplemental Table 3 ). This shift corresponds to approximately 75 and 93% protein binding, which is significantly lower than the binding observed for many other TKIs (7, 39) . For example, while the CEP-701 IC 50 for FLT3 inhibition only shifts 6-fold from RPMI with 10% FBS to 100% mouse plasma, the IC 50 shifts greater than 100-fold in 100% human plasma (from 2-3nM to an IC 50 of 700nM), which indicates plasma protein binding of >99% (7). This was the major reason for the failure of CEP-701 to show improved CR and survival rates in a Phase 3 clinical trial (5).
To explore the disparate plasma protein binding of TTT-3002 and CEP-701, the impact of the two major human plasma proteins known to bind many TKIs, AGP and HSA, was TTT-3002 was still strongly active at physiological AGP concentrations, achieving greater than 60% FLT3 inhibition at 2 mg/mL AGP (Fig. 6C) . The other major plasma protein capable of binding many drugs is human serum albumin (HSA). TTT-3002 and CEP-701 activities were not as greatly affected by physiological levels of HSA, the most abundant plasma protein (supplemental Fig. 2A ) (40) . Thus, TTT-3002 should require lower doses than CEP-701 to achieve sufficient concentrations of free drug in plasma due to lower protein binding to AGP.
TTT-3002 activity in human leukemia patient plasma
To further assess the likely activity of TTT-3002 in a clinical setting, human plasma samples were obtained from a panel of adult and pediatric AML patients at the time of diagnosis, when AGP levels are known to often be elevated. Ba/F3-ITD cells were then cultured in these plasma samples with the addition of 0-10nM TTT-3002 for 1 h (Fig.   6D ). TTT-3002 potently inhibits phosphorylation of FLT3/ITD in the human AML plasma samples, with an average IC 50 of 6.4 ± 2.6nM (n=5). There was no significant difference between phospho-FLT3 inhibition achieved in AML patient plasma samples relative to that achieved in normal adult plasma as determined in achieved 75-85% inhibition of FLT3 phosphorylation whereas CEP-701 was inactive under these conditions (Fig. 6E, F) . The CEP-701 result in plasma is in stark contrast to what was observed at the same concentrations in cell culture media with 10% FBS and remains the most likely explanation for its failure in clinical trials. We found that TTT-3002 was highly active across the AGP and HSA concentration ranges measured in the plasma samples (0.5-2 mg/mL AGP, 2.5-4.0 g/dL HSA) (supplemental Fig. 2B, C) . Another major factor that limits the efficacy of FLT3 TKIs in clinical trials, aside from lack of activity against FLT3/PMs and selection for TKI resistance mutations in FLT3/ITD, is the extensive protein binding for many TKIs that occurs in human plasma. In the case of CEP-701, the compound is >99.9% protein bound in plasma. Similar binding properties have also been reported for PKC412 (>99%), sorafenib (99.7%) and AC220 (99%) (7, 39, 41) . This large amount of protein binding limits the amount of free drug available to inhibit target, reducing the efficacy of some of these TKIs in clinical trials. shows more moderate protein binding in human plasma (93%). This predicts that the shift in the dose-response curve for TTT-3002 going from cell culture conditions with 10%FBS to human patients should not be as extreme as it is for some other TKIs. Thus, achieving a total level of ≥30nM should achieve >90% FLT3 inhibition, given the average IC 90 of 2nM against FLT3/ITD phosphorylation by Western blotting. These are the approximate levels that one would aim to achieve at the trough level of the drug and thus would help to determine dose and frequency of administration in a future clinical trial.
The extensive preclinical studies highlighted both here and in a previous manuscript (24) support the advancement of TTT-3002 toward human clinical trials. Further studies will be required to assess the safety and toxicity in nonrodent animal models before moving this compound into human clinical trials, where assessment of absorption, bioavailability, pharmacokinetics and pharmacodynamics can be determined. Drug dosing schedule and tolerance in humans will also need to be determined in Phase 1 trials before moving to trials in relapsed/refractory/resistant FLT3 mutant AML patients. DMSO  TTT-3  Sorafe  AC220  DMSO  TTT-3  Sorafe  AC220  DMSO  TTT-3  Sorafe  AC220  DMSO  TTT- 
